Keytruda 100 mg

Keytruda 100 mg

$4,000

Active ingredient: pembrolizumab 100 mg
Manufactured by: MSD
Country of origin: Belgium
Package language: English
1 vial

Description

Keytruda (pembrolizumab) is a prescription medicine used to treat:

  • a kind of skin cancer called melanoma
  • a kind of lung cancer called non–small cell lung cancer (NSCLC).
    • Keytruda (pembrolizumab) may be used alone when your lung cancer has spread (advanced NSCLC) and tests positive for “PD-L1” and as your first treatment if you have not received chemotherapy to treat your advanced NSCLC and your tumor does not have an abnormal “EGFR” or “ALK” gene, or
    • you have received chemotherapy that contains platinum to treat your advanced NSCLC, and it did not work or it is no longer working, and if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an EGFR or ALK inhibitor medicine and it did not work or is no longer working.
    • Keytruda (pembrolizumab) may be used with the chemotherapy medicines pemetrexed and carboplatin as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type of lung cancer called “nonsquamous”.
  • a kind of cancer called head and neck squamous cell cancer (HNSCC) that has returned or spread andyou have received chemotherapy that contains platinum and it did not work or is no longer working.
  • a kind of cancer called classical Hodgkin lymphoma (cHL) in adults and children when you have tried a treatment and it did not work or when your cHL has returned after you received 3 or more types of treatment.
  • a kind of bladder and urinary tract cancer called urothelial carcinoma. Keytruda (pembrolizumab) may be used when your bladder or urinary tract cancer:
    • has spread or cannot be removed by surgery (advanced urothelial cancer) and,
    • you are not able to receive chemotherapy that contains a medicine called cisplatin, or
    • you have received chemotherapy that contains platinum, and it did not work or is no longer working.
  • a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI-H) or a mismatch repair deficient (dMMR) solid tumor. Keytruda (pembrolizumab) may be used in adults and children to treat:
    • cancer that has spread or cannot be removed by surgery (advanced cancer), and
    • has progressed following treatment, and you have no satisfactory treatment options, or
    • you have colon or rectal cancer, and you have received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan but it did not work or is no longer working.

It is not known if Keytruda (pembrolizumab) is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).

  • a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for “PD‑L1.” Keytruda (pembrolizumab) may be used when your stomach cancer:
    • has returned or spread (advanced gastric cancer)
    • you have received 2 or more types of chemotherapy including fluoropyrimidine and chemotherapy that contains platinum, and it did not work or is no longer working, and
    • if your tumor has an abnormal “HER2/neu” gene, you also received a HER2/neu-targeted medicine and it did not work or is no longer working.

Common side effects of Keytruda (pembrolizumab)

feeling tired, itching, diarrhea, decreased appetite, rash, fever, cough, shortness of breath, pain in muscles, bones or joints, constipation, and nausea.

In children, feeling tired, vomiting and stomach-area (abdominal) pain, and increased levels of liver enzymes and decreased levels of salt (sodium) in the blood are more common than in adults.

These are not all the possible side effects of Keytruda (pembrolizumab). Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist.

 

[/su_expand]